arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Indaptus Therapeutics, Inc.

INDP
$4.03 ▲ +0.31 (+8.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
19 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Indaptus Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $468.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -12.6% ↗
FCF / Share $-0.02 ↗
Trailing P/E —
Price / Book 47.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.54M
↑ +43.9% —
FCF / Share Free cash flow per share
$-0.02
↑ +97.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -629.4% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.71x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters